The Unit coordinates international, multicentral clinical trials as well as local clinical trials. Among the Unit’s projects are studies into new drugs for treating breast cancer (early and advanced), lung cancer, colon cancer, ovarian cancer, pancreatic cancer and prostate cancer, as well as other solid malignant tumors.
List of Active Trials (updated August 2015)
Research Studies/Clinical Trials open to recruiting patients in Oncology Day Treatment

Type of Disease



Doctor/Senior Researcher

Pancreatic Cancer with BRCA Mutation

CTEP #8993

Stage 2 random study of patients with adenocarcinoma of the pancreas, manifesting the known mutation BRCA/PALB2, to be treated with chemotherapy using Gemcitabine and Cisplatin with or without Veliparib (part I).

Dr. Segal with the MSKCC Medical Center in New York

Stomach Cancer


Phase 1B study for examining the safety of the liposomal mitomycin-C derivative (Promitil) administered intravenously to patients with colo-rectal tumors.

Dr. Tachover

Cancer of the Rectum

Prospect N1048

Stage 2/3 trial for administering neoadjuvant FOLFOX with chemoradiation therapy before lower frontal rectal removal surgery for advanced localized tumors.

Dr. Segal in partnership with the ECOG Alliance

Metastatic Lung Cancer NSCLC

M-14-359 VELA

Stage 2 random trial, open label, multicentral, comparing Veliparib supplemented by Carboplatin and Paclitaxel with the scientist's choice of accepted chemotherapy for subjects who either smoke now or have done in the past, receiving cytotoxic chemotherapy for the first time for metastatic or advanced lung cancer of cells that are neither small or scaly (NSCLC).  

Dr. Heshing

Metastatic Breast Cancer BRCA


Stage 2 random, effectiveness and tolerance of Veliparib combined with Carboplatin and Paclitaxel compared to a placebo with Carboplatin and Paclitaxel in women with Metastatic Breast Cancer and BRCA1 or 2 Mutation.

Dr. Rosengarten

Breast Cancer HER2 Positive


Random study, open, phase 3, for evaluating the effectiveness and safety of Trastuzumab Emtansine (TDM1) compared to Trastuzumab (Herceptin), after surgery (adjuvant therapy) in patients with Breast Cancer HER2 Positive, who received treatment before surgery and are left with the pathological remains of the disease in the breast or in the lymph glands under the arms.  

Dr. Rosengarten

Breast Cancer HER2 Negative with BRCA Mutation


Stage 3 trial, random, open, controlled, of Niraparib, compared to the doctor's choice, in patients with Breast Cancer HER2 negative with a positive result for BRCA mutation in germ cells, which were treated in the past.

Dr. Rosengarten

Metastatic Breast Cancer HER2 Positive


Treatment with Neratinib combined with Capecitabine, as opposed to Lapatinib combined with Capecitabine, for patients with Metastatic Breast Cancer, HER2 Positive, who have previously received at least two treatment lines for HER2 within the metastatic disease framework.

Dr. Rosengarten

Metastatic Breast Cancer HER2 Negative, ER-PR Positive

16298 RAD223

Stage 2, random, double blind, with placebo, of Radium 223 – dichloride (RAD223), for treating Metastatic Breast Cancer with a negative result to HER2 and positive to hormone receptors, with metastasis in the bones, who have received hormonal therapy.

Dr. Isaacson

Cancer of the Ovaries, Fallopian Tube or Peritoneum


Controlled placebo test, phase 3, for treatment with Carboplatin and Paclitaxel with or without Veliparib, in parallel and later as preservation, in female subjects with Epithelial Serous Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer at stage 3 or 4 untreated in the past.

Dr. Rosengarten